Thu, April 19, 2012
Wed, April 18, 2012
Tue, April 17, 2012
Mon, April 16, 2012
Sun, April 15, 2012
[ Sun, Apr 15th 2012 ] - Market Wire
DaVita Announces CFO Transition
Sat, April 14, 2012
Fri, April 13, 2012
Thu, April 12, 2012
Wed, April 11, 2012
Tue, April 10, 2012
Mon, April 9, 2012
Fri, April 6, 2012
Thu, April 5, 2012
[ Thu, Apr 05th 2012 ] - Market Wire
April 30, 2012
Wed, April 4, 2012

Regeneron to Report First Quarter 2012 Financial and Operating Results and Host Conference Call and Webcast on April 26, 2012


//health-fitness.news-articles.net/content/2012/ .. onference-call-and-webcast-on-april-26-2012.html
Published in Health and Fitness on Thursday, April 12th 2012 at 13:11 GMT by Market Wire   Print publication without navigation


Regeneron to Report First Quarter 2012 Financial and Operating Results and Host... -- TARRYTOWN, N.Y., April 12, 2012 /PRNewswire/ --

Regeneron to Report First Quarter 2012 Financial and Operating Results and Host Conference Call and Webcast on April 26, 2012

[ ]

TARRYTOWN, N.Y., April 12, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)today announced that it will report its first quarter 2012 financial and operating results on Thursday, April 26, 2012, before the U.S. financial markets open.  The Company will host a conference call at 8:30 AM EDT that day.

Live audio of the conference call will be webcast online simultaneously.  A link to the webcast may be accessed from the 'Events and Presentations' page of Regeneron's website at [ www.regeneron.com ].  A replay of the conference call and webcast will be archived on the Company's website and will be available for 30 days.  

Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets two products in the United States, one for the treatment of neovascular (wet) age-related macular degeneration and another for the treatment of a rare inflammatory condition.  Additionally, Regeneron has three regulatory applications pending before the U.S. Food and Drug Administration (FDA) and 10 drug candidates in clinical development.  More information and recent news releases are available on the Regeneron website at [ www.regeneron.com ].

cellpadding="0" cellspacing="0" id="convertedTable" style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; BORDER-COLLAPSE: collapse; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">

Contact Information:                                                                                   

Manisha Narasimhan, Ph.D.                

Peter Dworkin

Investor Relations                                

Corporate Communications                               

914-847-5126                                       

914.847.7640                

[ Manisha.narasimhan@regeneron.com ]     

[ peter.dworkin@regeneron.com ]

SOURCE Regeneron Pharmaceuticals, Inc.

[ Back to top ]

RELATED LINKS
[ http://www.regeneron.com ]


Publication Contributing Sources